Holen Sie sich die Stockscreener-App
4.88
4.87%
-0.25
Handel nachbörslich:
5.05
0.17
+3.48%
Evoke Pharma Inc Aktie (EVOK) Neueste Nachrichten
Why Evoke Pharma Inc. stock attracts strong analyst attentionStrong Buy Recommendations - Newser
What makes Evoke Pharma Inc. stock price move sharplyVerified Chart Patterns - Newser
How Evoke Pharma Inc. stock performs during market volatilityFree Real-Time Stock Data - Newser
Small Cap Stocks Worth Watching – July 9th - Defense World
Promising Pharmaceutical Stocks To Watch Now – July 9th - Defense World
Evoke Pharma Shares Jump 50% Following Patent Approval for GIMOTI - MSN
Evoke Pharma skyrockets on patent allowance for diabetes nasal spray drug - Mugglehead Magazine
Evoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile In - Asianet Newsable
Evoke Pharma receives patent allowance for gastroparesis nasal spray By Investing.com - Investing.com South Africa
Evoke Pharma (EVOK) Soars 162.78% on Patent Extension - AInvest
Crude Oil Moves Higher; RxSight Shares Plunge - Benzinga
Evoke Pharma shares surge 24.57% intraday after receiving Notice of Allowance for U.S. patent application for GIMOTI®. - AInvest
Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On? - Benzinga
Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May - Benzinga
Evoke Pharma Shares Soar After Patent Allowance for Gastroparesis Treatment - MarketScreener
Evoke Pharma (EVOK) Stock Soars Following Positive Patent News - Stocks Telegraph
Evoke Pharma: Is the Bounce Back Real? - StocksToTrade
EVOK Stock: Boom or Bust? - timothysykes.com
Evoke Pharma (EVOK) Secures New Patent Approval for GIMOTI | EVO - GuruFocus
Evoke Pharma stock soars after receiving patent allowance for GIMOTI By Investing.com - Investing.com Nigeria
Evoke Pharma stock soars after receiving patent allowance for GIMOTI - Investing.com
Evoke Pharma (EVOK) Secures Key Patent for Gastroparesis Treatment | EVOK Stock News - GuruFocus
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 | EVOK Stock News - GuruFocus
Evoke Pharma, Inc. Receives Patent Allowance for GIMOTI® in Treatment of Gastroparesis Symptoms - Quiver Quantitative
Evoke Pharma Receives Notice of Allowance for U.S. Patent - GlobeNewswire
Major Patent Win: GIMOTI Locks Down 6 More Years of Exclusivity for Revolutionary Gastroparesis Spray - Stock Titan
Evoke Pharma Secures Patent for GIMOTI Treatment - TipRanks
GILT lands >$22M Tier-One satellite orders, boosts multi-orbit momentum | EVOK SEC FilingForm 8-K - Stock Titan
Evoke Pharma (NASDAQ:EVOK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Head to Head Review - Defense World
Evoke Pharma (NASDAQ:EVOK) Stock Price Crosses Below Two Hundred Day Moving Average – What’s Next? - Defense World
Spine Injury Solutions (OTCMKTS:SPIN) Stock Price Crosses Below 200-Day Moving Average – Should You Sell? - Defense World
Breakeven On The Horizon For Evoke Pharma, Inc. (NASDAQ:EVOK) - Yahoo Finance
Gastroparesis Treatment Market Booming Worldwide with - openPR.com
Diabetic Gastroparesis Pipeline 2025: Key Developments, - openPR.com
Geriatric Medicines Market Expands Globally with Aging - openPR.com
Diabetic Gastroparesis Treatment Market Size, Trends & - openPR.com
Global Geriatric Medicines Market Generated Opportunities, - openPR.com
Diabetic Gastroparesis Treatment Market in 2025-2032 Detailed - openPR.com
Evoke Pharma Holds Annual Meeting via Webcast - TipRanks
Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World
Barclays PLC Makes New $122,000 Investment in Innovator Equity Defined Protection ETF – 2 Yr to July 2026 (BATS:AJUL) - Defense World
Raymond James Financial Inc. Takes Position in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World
Evoke Pharma Reports Strong Q1 2025 Sales Growth - TipRanks
Evoke Pharma Reports First Quarter 2025 Financial Results and Pr - GuruFocus
Evoke Pharma, Inc. Q1 Loss Decreases, But Misses Estimates - Nasdaq
Evoke Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Evoke Pharma Q1 Operating Expenses USD 4.4 Million - marketscreener.com
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Evoke Pharma Reports 77% Increase in Q1 2025 Net Product Sales, Driven by GIMOTI Adoption and Provider Engagement - Nasdaq
Evoke Pharma (EVOK) to Release Earnings on Tuesday - Defense World
Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com - Defense World
EVOKEvoke Pharma Inc Latest Stock News & Market Updates - Stock Titan
StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
8.43%
1.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):